Immucell Corp vs. Intellia Therapeutics, Inc
Immucell Corp (ICCC) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| ICCC | NTLA | |
|---|---|---|
| Market Cap | $91.37 million | $1.80 billion |
| Revenue (TTM) | $30.68 million | $59.51 million |
| Net Income (TTM) | $787,373 | $-399,975,000 |
NTLA leads on 2 of 3 size & scale factors.
Valuation
| ICCC | NTLA | |
|---|---|---|
| P/E Ratio | 143.71 | — |
| Price / Book | 2.91 | 2.47 |
| Price / Sales | 2.98 | 30.24 |
ICCC and NTLA split the valuation factors evenly.
Profitability
| ICCC | NTLA | |
|---|---|---|
| Net Margin | 2.57% | -672.16% |
| Return on Equity | 2.51% | -54.96% |
ICCC leads on 2 of 2 profitability factors.
Risk & Sentiment
| ICCC | NTLA | |
|---|---|---|
| Short Interest | 0.20% | 2.43% |
ICCC leads on 1 of 1 risk & sentiment factors.
Dig deeper: ICCC overview, ICCC financials, NTLA overview, NTLA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.